ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
NewAmsterdam Pharma raises $196m through Series A funding round pharmaceutical-technology
January 18, 2021Clinical stage company NewAmsterdam Pharma (NAP) has raised $196m (€160m) through Series A funding round to support the full Phase III development of its ApoB and LDL-c lowering small molecule drug, obicetrapib. -
MSD’s CETP inhibitor cuts heart risk by 9 percent
pharmatimes
August 31, 2017MSD has revealed that its CETP inhibitor anacetrapib reduced the risk of major coronary events by 9 percent versus placebo in patients with cardiovascular disease already taking LDL-C lowering therapy alongside atorvastatin.
Pharma Sources Insight January 2025
